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Abstract
AIM: To study the results of stem-cell therapy under a 
Compassionate-use Program for patients with recurrent 
anal fistulae.
METHODS: Under controlled circumstances, and approved 
by European and Spanish laws, a Compassionate-use 
Program allows the use of stem-cell therapy for patients 
with very complex anal fistulae. Candidates had 
previously undergone multiple surgical interventions 
that had failed to resolve the fistulae, and presented 
symptomatic recurrence. The intervention consisted of 
limited surgery (with closure of the internal opening), 
followed by local implant of stem cells in the fistula-
Observational Study
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tract wall. Autologous expanded adipose-derived stem 
cells were the main cell type selected for implant. The 
first evaluation was performed on the 8th postoperative 
week; outcome was classified as response or partial 
response. Evaluation one year after the intervention 
confirmed if complete healing of the fistula was 
achieved. 
RESULTS: Ten patients (8 male) with highly recurrent 
and complex fistulae were treated (mean age: 49 
years, range: 28-76 years). Seven cases were non-
Crohn’s fistulae, and three were Crohn’s-associated 
fistulae. Previous surgical attempts ranged from 3 
to 12. Two patients presented with preoperative 
incontinence (Wexner scores of 12 and 13 points). 
After the intervention, six patients showed clinical 
response on the 8 th postoperative week, with a 
complete cessation of suppuration from the fistula. 
Three patients presented a partial response, with 
an evident decrease in suppuration. A year later, 
six patients (60%) remained healed, with complete 
reepithelization of the external opening. Postoperative 
Wexner Scores were 0 in six cases. The two patients 
with previous incontinence improved their scores from 
12 to 8 points and from 13 to 5 points. No adverse 
reactions or complications related to stem-cell therapy 
were reported during the study period.
CONCLUSION: Stem cells are safe and useful for 
treating anal fistulae. Healing can be achieved in severe 
cases, sparing fecal incontinence risk, and improving 
previous scoring.
Key words: Adipose-derived stem cells; Cell therapy; 
Compassionate use; Crohn’s disease; Fistula-in-ano
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Core tip: Our group has performed various clinical trials 
with adipose stem cells. Patients with very complex 
fistulae, multiple previous surgeries, and treatment 
failure are generally not able to enter these studies 
despite the benefit and “last chance” of cure. We 
present the results of a Compassionate-use Program, 
which enabled the application of stem-cell therapy to 
these patients, under strict regulations. Ten patients 
were treated, and after one year of follow-up, we 
conclude that adipose stem cells are effective and safe, 
and 60% of the patients achieved complete healing.
Garcia-Olmo D, Guadalajara H, Rubio-Perez I, Herreros MD, 
de-la-Quintana P, Garcia-Arranz M. Recurrent anal fistulae: 
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INTRODUCTION
A limited surgical treatment in recurrent perianal 
fistulae often results in new recurrence, whereas there 
is a high risk of fecal incontinence if an extensive 
surgical treatment is performed[1-3]. The use of stem 
cells to treat complex fistulae is a promising area of 
research[4,5], for they may help to regenerate damaged 
perianal tissue. Especially in Crohn’s disease, the 
presence of these cells could favor healing through 
anti-inflammatory and immunomodulatory effects[6-9]. 
Various randomized controlled trials using stem cells 
for the treatment of anal fistulae have already been 
conducted, and all of them show an excellent safety 
profile. Nevertheless, the real efficacy is currently 
difficutl to assess[5]. A recent Spanish study revealed 
that the mean annual global cost of conventional 
treatments for patients with Crohn’s disease and 
perianal fistulae is > € 8000/year[10].
According to current regulatory issues at the time 
(2002), our team started a clinical trial process in 
order to test the ability of adipose-derived stem cells 
(ASC) to improve healing in complex perianal fistulae, 
including those associated with Crohn’s disease. 
The chosen cell source was adipose tissue because 
the harvesting process for ASC following liposuction 
was simple and could be performed in our on-site 
laboratory[11]. To the date, we have finished a complete 
clinical trial process: a pilot study[12], and Phase Ⅱ[13] and 
Phase Ⅲ clinical trials[14]. Although a complex perianal 
fistula is the worst scenario, we observed satisfactory 
healing in our patients, without associated fecal 
incontinence. We are currently developing novel clinical 
trials directed to test different strategies in order to 
improve our results[5].
Some of the patients with multi-recurrent anal 
fistulae did not meet the strict eligibility criteria of 
clinical trials or were scheduled in control groups. The 
only option to treat these fistulae with stem cells was 
by “compassionate use”. To achieve this, the European 
regulatory laws and the Spanish Medicine Agency 
guidelines were followed in order to obtain regulatory 
permissions. Under the Compassionate-use Program, 
the surgical technique and the cells’ lineage is tailored 
for each patient, reinforcing the possibilities of cure, 
as opposed to the clinical trial setting. In these special 
cases, we performed minimal surgical maneuvers 
(limited surgery) directed to the conditioning of the 
surgical field, followed by implant of cells, in order to 
improve healing. This strategy enabled us to avoid 
anal sphincter injury and facilitated cell homing[6].
The aim of this paper is to report our experience 
in a clinical trial- complementary Compassionate-
use Program, and discuss the possible clinical uses of 
stem cells in the future, focusing on the treatment of 
complex and recurrent perianal fistulae.
Garcia-Olmo D et al . Stem-cell therapy: Recurrent anal fistulae
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MATERIALS AND METHODS
We present an observational study, including 10 
patients (8 male and 2 female) with recurrent perianal 
fistulae who had previously undergone at least three 
surgical interventions (maximum: 12, average: 6.2), 
with failure to resolve the fistula. The mean age of the 
patients was 49 years, and ranged from 28 to 76 years 
(Table 1). Seven patients presented complex non-
Crohn’s fistulae (four were Parks’ type Ⅲ)[15] and three 
patients had Crohn’s-associated perianal fistulae. Two 
of these patients complained of fecal incontinence at 
the moment of enrollment in this study, with a Wexner 
Score[16] > 10.
Autologous expanded adipose-derived stem cells 
(eASC) were selected in eight cases. Another case 
was treated using stromal vascular fraction (SVF) and 
in the last one, allogeneic adipose derived stem cells 
(Allo-eASC) were employed.
Both eASC (autologous and allogeneic) and SVF 
protocols were approved by the Ethics Committee of 
La Paz University Hospital in accordance with Spanish 
law, and by the Spanish Medical Agency according 
to European Medicine Agency (EMA) guidelines. All 
patients signed a detailed informed consent prior 
to any intervention, which included permission for 
data publication. Our institutional Committee on 
Human Experimentation (La Paz University Hospital) 
supervised all interventions performed. All ethical 
standards were in accord with those of the Helsinki 
Declaration (1975).
SVF from lipoaspirate
The liposuction was performed by a plastic surgeon 
and obtained 80-100 ml of fat. Phosphate buffered 
saline (PBS; Gibco of Thermo Fisher Scientific, 
Waltham, MA, United States) was used to wash the 
raw lipoaspirate and remove local anesthetics and 
cells. To extract the cellular fraction, the washed fat 
was digested with type Ⅰ collagenase (Gibco) at a final 
concentration of 0.075% in saline solution at 37 ℃ for 
45 min.
Collagenase was inactivated with Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco) containing 
fetal bovine serum (10% v/v). Cells in suspension 
were then centrifuged for 10 min (250 × g) and PBS 
was used again to wash the pellet. Centrifugation was 
repeated and afterwards the remaining erythrocytes 
were lysed by treating the suspension with ammonium 
chloride 160 mmol/L for 10 min at room temperature. 
To conclude the cellular extraction, a final wash and a 
filtration of the product through a 40 μm nylon mesh 
was performed.
Before injection, cells were suspended in sterile 
ringer-lactate solution (Griffols S.A., Barcelona, Spain). 
Morphologic determinations and phenotypic analyses 
were performed during product obtention. Data are 
partly published in García-Olmo et al[12]. The cell 
viability was always > 95% as determined by trypan-
blue (Sigma-Aldrich, St Louis, MO, United States).
Autologous stem cell expansion and preparation for 
implantation
The released cellular fraction (SVF) was seeded at 
2-3 × 104 cells/cm2. Culture was carried out in DMEM 
with 10% fetal bovine serum and 1% ampicillin/
streptomycin. No additional supplements were added. 
The atmospheric conditions were 37 ℃ with a 5% CO2 
atmosphere.
Cells were re-plated once 80% confluency was 
confirmed; their prior detachment was performed by 
trypsinization (trypsin-EDTA; Gibco). This cycle was 
repeated up to three times until the required number 
of cells for implantation was obtained. Due to logistics 
and personal issues, in two cases the cells were then 
frozen for preservation.
Morphologic determinations and phenotypic 
analyses were performed by flow cytometry during 
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Table 1  Study data
ID Sex Age 
(yr)
Crohn’s 
disease
Park’s 
classification
Previous 
surgical 
attempts
Initial 
incontinence 
score (Wexner)
Surgical technique Fibrin 
glue
Cells Response 
8th week
Incontinence 
score 8th 
week
Healing 
one year 
after
1 Male 58 No Ⅲ   8   1 Flap + deep curettage No eASC Yes 0 Yes
2 Male 43 No Ⅱ   4 Unknown IO closure + partial 
fistulectomy
Yes eASC Yes 4 No
3 Male 76 No Ⅲ   5   0 IO closure + deep curettage Yes eASC Partial 0 No
4 Male 57 No Ⅲ 12   0 IO closure + deep curettage Yes eASC Yes 0 Yes
5 Female 45 Yes Ⅳ (multiple 
tracts)
  6 12 IO closure + deep curettage Yes eASC Partial 8 Yes
6 Male 35 Yes Ⅱ (stenosis)   5 Unknown IO closure + deep curettage No eASC No 0 No
7 Male 40 Yes Ⅲ   3 Unknown IO closure + deep curettage Yes eASC Yes 0 Yes
8 Male 59 No Ⅱ 11 13 Flap + deep curettage No eASC 
Allog
Partial 5 No
9 Male 50 No I   3 Unknown Fistulotomy Yes eASC Yes 0 Yes
10 Female 28 No Ⅲ 5 + ileostomy Not evaluable Flap + partial fistulectomy Yes SVF Yes Not 
evaluable
Yes
IO: Internal opening; eASC: expanded adult stem cells; Allog: Allogeneic; SVF: Stromal vascular fraction.
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evaluation[19].
RESULTS
Of the ten highly recurrent perianal fistulae treated, 
6/10 (60%) showed a clinical response 8 wk after the 
procedure, and 3/10 (30%) showed a partial response. 
One year later, 6/10 (60%) remained healed, with 
the external opening being completely epithelialized 
(Table 1). Postoperative results of Wexner Scores for 
Incontinence[16] were 0 in 6 cases. In the two patients 
with previous fecal incontinence, the scoring improved 
from 12 to 8 and from 13 to 5. No adverse reactions 
or complications related to stem-cell therapy were 
reported during the study period.
No statistical relationships have been established 
between the use of fibrin glue, surgical approach or 
cell lineage, due to the small number and variability of 
patients.
DISCUSSION
Following strict regulations, we treated ten patients 
with recurrent perianal fistulae, achieving a 90% 
response and a complete healing after one year in 
six cases, with no associated incontinence. Moreover, 
in two cases, previous incontinence was reduced. It 
is important to remark that the performance of this 
therapeutic strategy does not produce injury to the 
anal sphincter, because intrasphincteric-tract resection 
is not required. Although this is not a randomized 
controlled trial, the results are similar to those already 
published[12-14]. 
ASCs enlarge the therapeutic arsenal for anal 
fistulae, and can be considered an interesting tool 
for the regeneration/repair of wounds or chronically 
damaged tissues. The specific mechanism of action 
of ASCs is still under study, but it has been widely 
demonstrated that these cells improve healing[6]. Two 
different biologic effects are responsible for this healing 
effect: proliferation and differentiation on the one 
hand, and immune regulation and local suppression of 
inflammation on the other[6].
According to the EMA, ASC treatments in the EU 
should be administered only under clinical trials or 
other controlled conditions, such as Compassionate-
use Programs. It is important to remark that all 
clinical uses of stem cells outside of these regulatory 
conditions are considered illegal. This is clearly stated 
in the law RD 1015/2009. In this way, in February 
2011, the EMA published a report on stem cell-based 
medicinal products. It expressed concerns about the 
unregulated use of medicinal products containing 
ASCs.
In this context, one of the limitations of our 
study is the small number of patients included. We 
believed that a limited surgical treatment supported 
by ASC could be beneficial for these patients; but only 
those that did not meet the inclusion criteria or were 
expansion. Mycoplasma was detected using a Myco 
Alert Mycoplasma Detection Kit (Cambrex Corp., 
East Rutherford, NJ, United States). Data are partly 
published in García-Olmo et al[12].
At least one week before the surgical intervention 
was scheduled, expanded ASCs were prepared (washed 
with PBS, trypsinized, and centrifuged). Their viability 
was checked (> 95%), and finally the cells were 
resuspended in ringer-lactate solution (Griffols S.A.) at 
the desired volume and concentration (depending on 
the fistula) for their immediate use.
Allogeneic stem cell expansion and preparation for 
implantation
These cells were manufactured from donors by Tigenix 
SAU (Madrid, Spain) according to EMA permissions 
and regulations from healthy donors. The expansion 
protocol was similar to that of autologous procedures.
Treatment procedure and evaluation of healing
All surgical procedures were performed at La Paz 
University Hospital (Madrid), by the same team of 
surgeons, belonging to the Colorectal Surgery Unit.
In all cases, a deep curettage of the tracts was first 
performed, and then the ASC suspension (50%) was 
injected through a long, fine needle into the tract walls. 
The injections were superficial; not deeper than 2 mm. 
In seven cases, the fistulous tract was sealed with 
fibrin glue (Baxter Inc., Deerfield, IL, United States) 
containing a portion (1 ml) of the cells. The fibrin 
glue was used as a sealant to finalize the procedure 
in order to ensure cells remained in the fistulous area. 
The main reason for injecting a percentage of the 
ASC into the fibrin glue was to have a reservoir in 
the area so they could act for longer. However, recent 
investigations indicate that cells alone are sufficient for 
a therapeutic effect[17,18].
 In very complex perianal fistulae, a partial 
fistulectomy was performed without removing intra-
sphincteric tracts. The closure of the internal opening 
was achieved by stitches in six cases and by a mucosal 
advancement-flap in three cases. In the remaining 
patient, a fistulotomy was performed.
Treatment outcomes
A first evaluation was performed on the 8th pos-
toperative week, and a final evaluation was scheduled 
one year after the procedure (although patients 
attended the outpatient clinic in between, at variable 
intervals). Response was defined as a complete 
cessation of suppuration on week 8, despite not 
achieving a complete re-epithelization. Partial response 
was defined as an evident decrease in suppuration. 
Healing was defined as no suppuration from the 
external orifice, achieving a complete re-epithelization 
after one year of follow-up. These intervals of time 
for follow-up were selected following published data 
about the best periods for long-term fistula follow-up 
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scheduled in control groups of our clinical trials could 
be selected for the present study.
Various randomized controlled trials using ASCs for 
the treatment of anal fistulae have been conducted, 
and all of them show an excellent safety profile. 
Nevertheless, the actual efficacy is difficult to assess. 
To date, there are 11 published papers including data 
on stem cell-based treatment of anal fistulae (Table 
2). The first one was published in 2003[11], and the last 
was published very recently, in 2013[20]. Eight of these 
have been published by Spanish groups[11-14,17,21-23], 
two other papers come from South Korea[20,24], and 
one from Italy[25]. The majority refer to ASC treatment 
of Crohn’s disease-related fistulae. The Italian study 
was the only one to select bone marrow as the ASC 
source for the treated fistula[25]. The rest of the studies 
employed autologous or allogeneic cells from adipose 
tissue. In all studies, cells were expanded, and a wide 
range of doses applied. Except for the Italian study[25], 
all procedures included closure of the internal opening, 
and in all cases the cell injections were intra-lesional. 
Over three hundred patients have been enrolled in 
these studies and the most important result is the 
assurance of the excellent safety profile of stem cells: 
no serious cell-related adverse events were described. 
Regarding efficacy, results show very different profiles, 
but about 40%-60% of patients achieved healing (Table 
3).
The cost of the treatment is another important 
issue. Nowadays, the production cost of expanded 
ASCs (Good Manufacturing Practice compliant) can 
range from € 8000-12000, though the production 
could be reduced to € 3000-4000 without expansion[13]. 
We estimate that a high scale industrial production 
could significantly reduce the expenses. A reasonable 
strategy that we propose, considering the high cost of 
cell expansion and our previous results, would be to 
apply a first treatment with SVF, freeze a portion of the 
cells obtained, and propose a second treatment with 
expanded cells in cases achieving no response after 
eight weeks. 
Treatment of recurrent fistulae is a difficult surgical 
challenge. In these patients, the pursuit of healing 
usually involves multiple operations, with a subsequent 
perianal scarring and distortion. In the most complex 
cases, the condition is worsened by the accompanying 
fecal incontinence. Therefore, these individuals are 
progressively more difficult to treat, resulting in the 
exasperation of both the patient and the surgeon[26]. 
In these cases, wound healing is a critical issue, and 
indeed, new approaches are needed. For the reasons 
outlined earlier, we believe that once available, ASCs 
will fulfill a clear and previously unmet medical need, 
helping to improve the healing and hence the quality 
of life of patients with recurrent perianal fistulae. 
In conclusion, limited surgery supported by ASCs 
may constitute as a new therapeutic strategy in the 
treatment of recurrent fistulae.
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Table 2  Published studies on stem cell therapy for anal fistulae
Ref. Year Condition Study design Cell source Cell quantity (dose) Intervention model
García-Olmo et al[11] 2003 Recto-vaginal fistula in Crohn’s 
disease
Case report Autologous eASC 1 × 107 Single arm
García-Olmo et al[12] 2005 enterocutaneous, recto-vaginal, 
perianal fistula in Crohn’s 
disease
Phase Ⅰ Autologous eASC 1-3 × 107 re-suspended 
in fibrin glue
Single arm
García-Olmo et al[13] 2009 Perianal fistula with or without 
Crohn’s disease
Phase Ⅱ Autologous eASC Not specified Two arms: fibrin glue, 
fibrin glue + eASC
García-Olmo et al[22] 2010 Recto-vaginal fistula in Crohn’s 
disease
Case report Allogenic eASC Not specified Single arm
Ciccocioppo et al[25] 2011 enterocutaneous and complex 
perianal fistula in Crohn's 
disease
Case report expanded 
autologous bone 
marrow
5 × 107 Single arm
Cho et al[24] 2012 Perianal fistula in Crohn’s 
disease
Phase Ⅰ Autologous eASC Not specified Single arm: dose 
escalation study
Herreros et al[14] 2012 Complex perianal fistula 
without Crohn’s disease
Phase Ⅲ Autologous eASC 2 × 107 then 4 × 107 if no 
effect
Three arms: fibrin glue, 
eASC, fibrin glue + eASC
Herreros et al[14] 2012 Complex perianal fistula 
without Crohn’s disease
Observational Autologous eASC 2 × 107 then 4 × 107 if no 
effect
Three arms: fibrin glue, 
eASC, fibrin glue + eASC
Guadalajara et al[23] 2012 Perianal fistula with or without 
Crohn’s disease
Observational Autologous eASC Not specified Two arms: fibrin glue, 
fibrin glue + eASC
de la Portilla et al[17] 2012 Perianal fistula in Crohn’s 
disease
Phase Ⅰ/Ⅱ Allogeneic eASC 2 × 107 then 4 × 107 if no 
effect
Single arm
Lee et al[20] 2013 Perianal fistula in Crohn’s 
disease
Phase Ⅱ Autologous eASC Depending on the 
fistula. Re-dosing (1.5 
times) if no effect
Single arm
SAe: Serious adverse events (those requiring hospital admission > 24 h); eASC: expanded adult stem cells.
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Background
The concept of stem cell therapy came from the possibility of obtaining an 
immature cell that could differentiate into a specific lineage if placed in the 
correct environment. One of the first examples was the transplantation of stem 
cells in hematologic patients, which could achieve the regeneration of normal 
marrow, and is now widely used. Following this idea, researchers raised the 
question of whether or not there could be different stem cells for other organs, 
or even embryonic cells that could develop into any of them. The study and 
therapeutic use of these types of cells could be the answer for many incurable 
injuries and diseases.
Research frontiers
Complex and recurrent anal fistulae (whether associated or not to Crohn’s disease), 
constitute an important surgical problem, which can be difficult to solve. Many 
strategies have been proposed to achieve healing, including different surgical 
techniques, including fibrin glues and plugs. The application of stem cells in the 
fistula tract promotes the “closure” of the fistula by stimulating the regeneration 
of the tissue, both by direct growth and immunomodulatory effects. The exact 
mechanisms by which stem cells induce healing are still under investigation.
Innovations and breakthroughs
An increasing number of randomized controlled trials have tested the 
application of adipose-derived stem cells (ASCs) in perianal fistulae, with 
variable rates of success. In the present study, we applied ASCs to the worst 
patients, those with recurrent fistulae despite multiple previous treatments 
and interventions. In these desperate cases, even a partial response to the 
treatment was a success, as patients’ distress was a constant after so many 
failures. ACSs were remarkably effective and we achieved healing in 60% after 
one year of follow-up.
Applications
This study, and various others in a randomized controlled trial setting, suggests that 
the surgical application of stem cells in anal fistula tract is a potentially therapeutic 
strategy that could resolve even the most recurrent and complex fistulae. In the 
same direction, ACSs are being used for the regeneration of skin, cartilage, bone, 
cornea, endothelium, etc. Applications to other organs, such as the heart and 
lung, and the nervous system have raised high expectations in the field. Research 
continues, and new applications are sure to develop in the near future.
Terminology
An anal fistula is an abnormal conduct communicating the anal canal with the 
perianal skin. The fistula tract typically breaks through the sphincters, and 
can have multiple ramifications. If one of the openings is blocked, an abscess 
occurs, which can worsen the condition. Drainage of these abscesses and 
surgical attempts to close the fistula can damage the muscle of the sphincters 
and cause fecal incontinence. The former, associated to suppuration and 
pain are the most common symptoms, creating a permanent discomfort for 
patients. Adult (somatic) stem cells are undifferentiated cells that can be found 
in differentiated tissue (such as bone, fat, and muscle) and have the potential 
to give rise to the specialized cell types present in the tissue from which 
they originate. A stem cell fulfills three characteristics: self-renewal capacity, 
differentiation potential, and in vivo engraftment capacity. Stem cell therapy: use 
of stem cells to replace those from damaged or diseased tissue. The source of 
the cells can either be the patient (autologous), another individual (allogeneic), 
or an animal (xenogeneic).
Peer-review
A good and interesting study even though it includes only ten patients. 
However, the results are very useful to speculate about the best current 
treatment of recurrent complex fistulae. It will be interesting if a randomized 
cross-over multicenter study can confirm these results with stem cell therapy in 
the complex anal fistulae.
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Table 3  Outcomes of published clinical experience of stem cell treatment for anal fistula
Ref. Procedure No. of patients treated Healed (n) Follow-up (mo) Recurrence (n) SAE (n)
García-Olmo et al[11] Closure of IO. Injection in 
site, without fibrin glue
1   1   3 0 0
García-Olmo et al[12] Cells resuspended in fibrin 
glue. Injection in site
9   6 12 Not specified 0
García-Olmo et al[13] Closure of IO. Injection in 
site
Fibrin glue: 25
Fibrin glue + eASC: 24
Fibrin glue: 3 
Fibrin glue + eASC: 17
12 Fibrin glue: 0
Fibrin glue + 
eASC: 2
4 (1 related to 
fibrin glue, others 
unrelated)
García-Olmo et al[22] Closure of IO. Injection in 
site, without fibrin glue
1   1 36 1 0
Ciccocioppo et al[25] Four injections in site 10   7 12 0 0
Cho et al[24] Closure of IO and fibrin 
glue. Injection in site
9   3 15 0 0
Herreros et al[14] Closure of IO. Injection in 
site
eASC: 64
Fibrin glue + eASC: 60
Fibrin glue: 59
eASC: 27
 Fibrin glue + eASC: 24
Fibrin glue: 23
  6 eASC: 0
 Fibrin glue + 
eASC: 4
 Fibrin glue: 0
4 unrelated to 
study treatment
Herreros et al[14] Closure of IO. Injection in 
site
Not specified eASC: 57%
Fibrin glue+ eASC: 
52.4%
Fibrin glue: 37.3%
12 Not specified 1 unrelated to 
study treatment
Guadalajara et al[23] Closure of IO. Injection in 
site
Fibrin glue: 13 Fibrin 
glue + eASC: 21
Fibrin glue: 3
Fibrin glue + eASC: 10
38 Fibrin glue: 1 
Fibrin glue + 
eASC: 5
0
de la Portilla et al[17] Closure of IO. Injection in 
site, without fibrin glue
24   9   4 Not specified 2 unrelated to 
study treatment
Lee et al[20] Injection in site and fibrin 
glue
43 27 12 4 0
IO: Internal opening; SAe: Serious adverse events (those requiring hospital admission > 24 h); eASC: expanded adult stem cells.
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